Guardian Australia, March 8th Incorrect assumptions are being made that gender equality has been achieved despite disturbing and comprehensive evidence to the contrary, an investigation by Australia’s sex discrimination commissioner, Kate Jenkins, has found. “There are many different voices in this, and my voice is tied to having spoken to rural women, LGBTI women, older women, women with...
nam/aidsmap, Published: 22 February 2017 A study of PrEP users presented last week showed that PrEP users had very high rates of STI diagnosis – in the order of 20 times higher than among HIV-negative gay men in the general population. The evidence that STIs increased further while people were on PrEP was, however, a lot more ambiguous. The problem in proving that PrEP has any causal relationship...
BETA Blog, September 8, 2016 How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day? A recent article published in The Lancet HIV provides insight into this very question. Read more here Access Lancet HIV abstract here (for full text please see your...
HRC Foundation, August 2016 The HRC Foundation, in partnership with Whitman-Walker Health, released Safer Sex for Trans Bodies, a comprehensive sexual health guide for transgender and gender expansive people and their partners. The guide is written by and for members of the transgender community and offers them a long-overdue resource on potentially life-saving and affirming practices, from...
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...
nam, 27 July 2015
An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among those at the highest risk of HIV.
Read more here